Data / Drug companies / Interleukin-23 Antagonist
Interleukin-23 Antagonist drugs: 12 drugs from 15 companies in the FDA NDC directory
Interleukin-23 Antagonist is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 66 products in this class from 15 companies, covering 12 drugs by generic name. The main marketing category is biologics (BLA), and the newest product started marketing on June 12, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 15Companies
- 66Products
- 12Drugs by generic name
Drugs in the Interleukin-23 Antagonist class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Ustekinumab-ttwe | 9 | 3 |
| Ustekinumab | 10 | 2 |
| Ustekinumab-aekn | 8 | 2 |
| Ustekinumab-auub | 7 | 1 |
| Risankizumab-rzaa | 6 | 1 |
| Ustekinumab-aauz | 6 | 1 |
| Mirikizumab-mrkz | 5 | 1 |
| Ustekinumab-hmny | 4 | 1 |
| Ustekinumab-stba | 4 | 1 |
| Guselkumab | 3 | 1 |
| Ustekinumab-srlf | 3 | 1 |
| Tildrakizumab-asmn | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Janssen Biotech, Inc. | 9 | injection, solution; injection | Biologics (BLA) | April 1, 2025 |
| Nuvaila Limited | 7 | injection, solution | Biologics (BLA) | January 1, 2025 |
| Teva Pharmaceuticals USA, Inc. | 7 | injection, solution | Biologics (BLA) | December 23, 2025 |
| AbbVie Inc. | 6 | injection; injection, solution | Biologics (BLA) | June 12, 2026 |
| Fresenius Kabi USA, LLC | 6 | injection, solution; solution | Biologics (BLA) | November 15, 2025 |
| Eli Lilly and Company | 5 | injection, solution | Biologics (BLA) | October 23, 2025 |
| Biocon Biologics Inc. | 4 | injection, solution; solution | Biologics (BLA) | February 22, 2025 |
| Celltrion USA, Inc. | 4 | injection, solution | Biologics (BLA) | April 13, 2026 |
| Hikma Pharmaceuticals USA Inc. | 4 | injection | Biologics (BLA) | October 27, 2025 |
| Quallent Pharmaceuticals Health LLC | 4 | injection, solution | Biologics (BLA) | April 15, 2025 |
| Accord BioPharma Inc. | 3 | injection | Biologics (BLA) | October 18, 2024 |
| Sandoz Inc | 3 | injection, solution | Biologics (BLA) | February 22, 2025 |
| Cordavis Limited | 2 | injection, solution | Biologics (BLA) | May 1, 2025 |
| A-S Medication Solutions | 1 | injection, solution | Biologics (BLA) | March 12, 2025 |
| Sun Pharmaceutical Industries, Inc. | 1 | injection, solution | Biologics (BLA) | August 6, 2018 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 47 | 71.2% |
| Injection | 15 | 22.7% |
| Solution | 4 | 6.1% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.